674 / 1173
1/03/2016
13
EGFR inhibition + RCT in HNSCC
•
Benefit with
chemotherapy
?
•
Initial results
•
Triplet did not improve PFS or OS
•
EGFr inhibition cannot replace CDDP
•
Cetuximab was associated with higher rates of mucositis
and skin reactions
EGFR inhibition + RCT in rectal cancer
•
Relatively low pCR in pts receiving cetuximab along
with CRT as preop R\ in rectal cancer in phase I/II
26
Machiels Ann Oncol 2007
pCR = 5% (2/37)
pCR = 9% (4/45)
Rödel C Int J Radiat Oncol Biol Phys 2008
Cetuximab, capecitabine, oxaliplating and RT
Cetuximab, capecitabine, and RT